Document Detail


A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusions.
MedLine Citation:
PMID:  3315579     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to determine the dose-response relationship of anisoylated plasminogen streptokinase activator complex (APSAC) by means of a between group double-blind comparison of the new agent and placebo. 50 patients with symptoms of acute myocardial infarction of less than 6 hours duration and whose coronary artery occlusion had been confirmed by coronary angiography were randomly allocated to 5 treatment groups (15, 20, 25 or 30U of APSAC, or placebo) and treatment was given as an intravenous injection over 2 minutes. Angiography was performed again at 15, 30, 45, 60 and 90 minutes and the films were assessed centrally by 2 independent cardiologists. Six patients were excluded from the angiographic analysis, 4 because their angiograms revealed patent arteries before APSAC was administered, 1 patient was excluded because streptokinase had been infused just after randomisation because of cardiogenic shock and 1 because the angiogram was not available due to problems in the film development. Clinical and laboratory examinations carried out for 72 hours after treatment showed that the drug was well tolerated. The reperfusion rates were as follows: placebo, 0/9; APSAC 15U, 5/8; APSAC 20U, 5/9; APSAC 25U, 6/9; APSAC 30U, 5/9. Reperfusion was achieved in 60% of treated patients but no dose relationship was revealed.
Authors:
A Leizorovicz; G Durrieu; J P Boissel
Related Documents :
1791089 - Anti-streptokinase levels in indian patients.
6404289 - Reduction of infarct size in patients with inferior infarction with intravenous glycery...
2495909 - Comparison of tissue plasminogen activator and streptokinase in the management of acute...
10761189 - Magnesium and calcium concentration in the abdominal aorta of patients deceased by isch...
21527739 - Disruption of hexokinase ii-mitochondrial binding blocks ischemic preconditioning and c...
3276409 - The western washington intravenous streptokinase in acute myocardial infarction randomi...
15476569 - Constrictive pericarditis versus restrictive cardiomyopathy: challenges in diagnosis an...
23579069 - Electrophysiological changes in heart failure and their implications for arrhythmogenesis.
8019709 - Abnormal automaticity as mechanism of atrial tachycardia in the human heart--electrophy...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  133-7     Citation Subset:  IM    
Affiliation:
Unite de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Coronary Angiography
Dose-Response Relationship, Drug
Double-Blind Method
Female
Fibrinolytic Agents / administration & dosage*,  adverse effects
Follow-Up Studies
Humans
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction / drug therapy*
Plasminogen / administration & dosage*,  adverse effects
Random Allocation
Streptokinase / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Physiological balance of haemostasis and bleeding.
Next Document:  Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase...